Trump to Launch Federal Research on Psychedelic Drug Ibogaine for PTSD
Trump plans to boost research on ibogaine for PTSD in veterans, despite safety concerns and its illegal status in the US.
/ 3 items
#HELP↓
Helus Pharma's HLP004 Phase 2: Small Study, Promising but Limited Signals
Helus Pharma's (Cybin/HELP) HLP004 Phase 2 trial shows potential adjunctive benefits in GAD but small size, 39% remission, no approval, injection format, and Phase 3 years away limit broad claims.
One DMT Dose Relieved Depression for Up to 6 Months
A new clinical trial published in Nature Medicine found that one dose of DMT (SPL026) significantly reduced depression symptoms in two weeks — with effects lasting up to six months for some patients.